

## REFERENCES

- [1] Weissman D, Fauci AS. Role of dendritic cells in immunopathogenesis of human immunodeficiency virus infection. *Clin Microbiol Rev.* 1997;10(2):358-67.
- [2] Carbonneil C, Donkova-Petrini V, Aouba A, Weiss L. Defective dendritic cell function in HIV-infected patients receiving effective highly active antiretroviral therapy: neutralization of IL-10 production and depletion of CD4+CD25+ T cells restore high levels of HIV-specific CD4+ T cell responses induced by dendritic cells generated in the presence of IFN-alpha. *J Immunol.* 2004;172(12):7832-40.
- [3] Mosca PJ, Hobeika AC, Clay TM, Nair SK, Thomas EK, Morse MA, et al. A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. *Blood.* 2000;96(10):3499-504.
- [4] Vremec D, Pooley J, Hochrein H, Wu L, Shortman K. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. *J Immunol.* 2000;164(6):2978-86

- [5] Foussat A, Bouchet-Delbos L, Berrebi D, Durand-Gasselín I, Coulomb-L'Hermine A, Krzysiek R, et al. Deregulation of the expression of the fractalkine/fractalkine receptor complex in HIV-1-infected patients. *Blood*. 2001;98(6):1678-86.
- [6] McIlroy D, Autran B, Clauvel JP, Oksenhendler E, Debre P, Hosmalin A. Low CD83, but normal MHC class II and costimulatory molecule expression, on spleen dendritic cells from HIV+ patients. *AIDS Res Hum Retroviruses*. 1998;14(6):505-13.
- [7] Donaghy H, Gazzard B, Gotch F, Patterson S. Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1. *Blood*. 2003;101(11):4505-11.
- [8] Smed-Sorensen A, Lore K, Walther-Jallow L, Andersson J, Spetz AL. HIV-1-infected dendritic cells up-regulate cell surface markers but fail to produce IL-12 p70 in response to CD40 ligand stimulation. *Blood*. 2004;104(9):2810-7.
- [9] Granelli-Piperno A, Golebiowska A, Trumfheller C, Siegal FP, Steinman RM. HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation. *Proc Natl Acad Sci U S A*. 2004;101(20):7669-74.

- [10] Garcia F, Lejeune M, Climent N, Gil C, Alcami J, Morente V, et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. *J Infect Dis.* 2005;191(10):1680-5.
- [11] Chougnet C, Cohen SS, Kawamura T, Landay AL, Kessler HA, Thomas E, et al. Normal immune function of monocyte-derived dendritic cells from HIV-infected individuals: implications for immunotherapy. *J Immunol.* 1999;163(3):1666-73.
- [12] McMichael AJ. HIV vaccines. *Annu Rev Immunol.* 2006;24:227-55.
- [13] Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. *Nat Med.* 2004;10(12):1359-65.
- [14] Engelmayer J, Larsson M, Lee A, Lee M, Cox WI, Steinman RM, et al. Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8<sup>+</sup> and CD4<sup>+</sup> T-cell responses from chronically infected individuals. *J Virol.* 2001;75(5):2142-53.
- [15] Sapp M, Engelmayer J, Larsson M, Granelli-Piperno A, Steinman R, Bhardwaj N. Dendritic cells generated from blood monocytes of HIV-1 patients are not infected and act as competent antigen presenting cells eliciting potent T-cell responses. *Immunol Lett.* 1999;66(1-3):121-8.

- [16] Kundu SK, Engleman E, Benike C, Shapero MH, Dupuis M, van Schooten WC, et al. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. *AIDS Res Hum Retroviruses*. 1998;14(7):551-60.
- [17] Hahn BH, Shaw GM, De Cock KM, Sharp PM. AIDS as a zoonosis: scientific and public health implications. *Science*. 2000;287(5453):607-14.
- [18] Hu DJ, Dondero TJ, Rayfield MA, George JR, Schochetman G, Jaffe HW, et al. The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention. *Jama*. 1996;275(3):210-6.
- [19] Grez M, Dietrich U, Balfe P, von Briesen H, Maniar JK, Mahambre G, et al. Genetic analysis of human immunodeficiency virus type 1 and 2 (HIV-1 and HIV-2) mixed infections in India reveals a recent spread of HIV-1 and HIV-2 from a single ancestor for each of these viruses. *J Virol*. 1994;68(4):2161-8.
- [20] Greene WC. AIDS and the immune system. *Sci Am*. 1993;269(3):98-105.
- [21] Rosen CA. Regulation of HIV gene expression by RNA-protein interactions. *Trends Genet*. 1991;7(1):9-14.

- [22] Simon F, Mauclore P, Roques P, Loussert-Ajaka I, Muller-Trutwin MC, Saragosti S, et al. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. *Nat Med.* 1998;4(9):1032-7.
- [23] Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, et al. Origin of HIV-1 in the chimpanzee *Pan troglodytes troglodytes*. *Nature.* 1999;397(6718):436-41.
- [24] Moore J, Anderson R. The WHO and why of HIV vaccine trials. *Nature.* 1994;372(6504):313-4.
- [25] Louwagie J, McCutchan FE, Peeters M, Brennan TP, Sanders-Buell E, Eddy GA, et al. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. *Aids.* 1993;7(6):769-80.
- [26] Chan DC, Kim PS. HIV entry and its inhibition. *Cell.* 1998;93(5):681-4.
- [27] Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. *Science.* 1998;280(5371):1884-8.
- [28] Zheng YH, Lovsin N, Peterlin BM. Newly identified host factors modulate HIV replication. *Immunol Lett.* 2005;97(2):225-34.

- [29] Hiscott J, Kwon H, Genin P. Hostile takeovers: viral appropriation of the NF-kappaB pathway. *J Clin Invest.* 2001;107(2):143-51.
- [30] Pollard VW, Malim MH. The HIV-1 Rev protein. *Annu Rev Microbiol.* 1998;52:491-532.
- [31] Pantaleo G, Fauci AS. Immunopathogenesis of HIV infection. *Annu Rev Microbiol.* 1996;50:825-54.
- [32] Clark SJ, Saag MS, Decker WD, Campbell-Hill S, Roberson JL, Veldkamp PJ, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. *N Engl J Med.* 1991;324(14):954-60.
- [33] Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. *N Engl J Med.* 1991;324(14):961-4.
- [34] Tindall B, Cooper DA. Primary HIV infection: host responses and intervention strategies. *Aids.* 1991;5(1):1-14.
- [35] Graziosi C, Pantaleo G, Demarest JF, Cohen OJ, Vaccarezza M, Butini L, et al. HIV-1 infection in the lymphoid organs. *Aids.* 1993;7 Suppl 2:S53-8.

- [36] Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. *Nature*. 1993;362(6418):355-8.
- [37] Pantaleo G, Graziosi C, Fauci AS. New concepts in the immunopathogenesis of human immunodeficiency virus infection. *N Engl J Med*. 1993;328(5):327-35.
- [38] Pantaleo G, Graziosi C, Fauci AS. The role of lymphoid organs in the immunopathogenesis of HIV infection. *Aids*. 1993;7 Suppl 1:S19-23.
- [39] Pantaleo G, Graziosi C, Demarest JF, Cohen OJ, Vaccarezza M, Gantt K, et al. Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. *Immunol Rev*. 1994;140:105-30.
- [40] Graziosi C, Pantaleo G, Gantt KR, Fortin JP, Demarest JF, Cohen OJ, et al. Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. *Science*. 1994;265(5169):248-52.
- [41] Haynes BF, Pantaleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. *Science*. 1996;271(5247):324-8.

- [42] Pantaleo G, Graziosi C, Butini L, Pizzo PA, Schnittman SM, Kotler DP, et al. Lymphoid organs function as major reservoirs for human immunodeficiency virus. *Proc Natl Acad Sci U S A*. 1991;88(21):9838-42.
- [43] Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. *Nature*. 1993;362(6418):359-62.
- [44] Piatak M, Jr., Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. *Science*. 1993;259(5102):1749-54.
- [45] Phair JP. Keynote address: variations in the natural history of HIV infection. *AIDS Res Hum Retroviruses*. 1994;10(8):883-5.
- [46] Lifson AR, Buchbinder SP, Sheppard HW, Mawle AC, Wilber JC, Stanley M, et al. Long-term human immunodeficiency virus infection in asymptomatic homosexual and bisexual men with normal CD4+ lymphocyte counts: immunologic and virologic characteristics. *J Infect Dis*. 1991;163(5):959-65.
- [47] Levy JA. HIV pathogenesis and long-term survival. *Aids*. 1993;7(11):1401-10.



- [48] Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. *N Engl J Med*. 1995;332(4):228-32.
- [49] Cease KB, Berzofsky JA. Toward a vaccine for AIDS: the emergence of immunobiology-based vaccine development. *Annu Rev Immunol*. 1994;12:923-89.
- [50] Carlson JR, McGraw TP, Keddie E, Yee JL, Rosenthal A, Langlois AJ, et al. Vaccine protection of rhesus macaques against simian immunodeficiency virus infection. *AIDS Res Hum Retroviruses*. 1990;6(11):1239-46.
- [51] Cranage MP, Polyanskaya N, McBride B, Cook N, Ashworth LA, Dennis M, et al. Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. *AIDS Res Hum Retroviruses*. 1993;9(1):13-22.
- [52] Desrosiers RC, Wyand MS, Kodama T, Ringler DJ, Arthur LO, Sehgal PK, et al. Vaccine protection against simian immunodeficiency virus infection. *Proc Natl Acad Sci U S A*. 1989;86(16):6353-7.
- [53] Murphey-Corb M, Martin LN, Davison-Fairburn B, Montelaro RC, Miller M, West M, et al. A formalin-inactivated whole SIV vaccine confers protection in macaques. *Science*. 1989;246(4935):1293-7.

- [54] Sutjipto S, Pedersen NC, Miller CJ, Gardner MB, Hanson CV, Gettie A, et al. Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals. *J Virol.* 1990;64(5):2290-7.
- [55] Berman PW, Groopman JE, Gregory T, Clapham PR, Weiss RA, Ferriani R, et al. Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. *Proc Natl Acad Sci U S A.* 1988;85(14):5200-4.
- [56] Eichberg JW, Zarling JM, Alter HJ, Levy JA, Berman PW, Gregory T, et al. T-cell responses to human immunodeficiency virus (HIV) and its recombinant antigens in HIV-infected chimpanzees. *J Virol.* 1987;61(12):3804-8.
- [57] Haigwood NL, Nara PL, Brooks E, Van Nest GA, Ott G, Higgins KW, et al. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. *J Virol.* 1992;66(1):172-82.
- [58] Lasky LA, Groopman JE, Fennie CW, Benz PM, Capon DJ, Dowbenko DJ, et al. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. *Science.* 1986;233(4760):209-12.

- [59] Allen PM, Unanue ER. Differential requirements for antigen processing by macrophages for lysozyme-specific T cell hybridomas. *J Immunol.* 1984;132(3):1077-9.
- [60] Norman PS, Ishizaka K, Lichtenstein LM, Adkinson NF, Jr. Treatment of ragweed hay fever with urea-denatured antigen E. *J Allergy Clin Immunol.* 1980;66(4):336-41.
- [61] Streicher HZ, Berkower IJ, Busch M, Gurd FR, Berzofsky JA. Antigen conformation determines processing requirements for T-cell activation. *Proc Natl Acad Sci U S A.* 1984;81(21):6831-5.
- [62] Takatsu K, Ishizaka K. Reaginic antibody formation in the mouse. VI. Suppression of IgE and IgG antibody responses to ovalbumin following the administration of high dose urea-denatured antigen. *Cell Immunol.* 1975;20(2):276-89.
- [63] Chakrabarti S, Robert-Guroff M, Wong-Staal F, Gallo RC, Moss B. Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. *Nature.* 1986;320(6062):535-7.
- [64] Hu SL, Kosowski SG, Dalrymple JM. Expression of AIDS virus envelope gene in recombinant vaccinia viruses. *Nature.* 1986;320(6062):537-40.

- [65] Hanna MG, Jr., Peters LC, Hoover HC, Jr. Fundamentals of active specific immunotherapy of cancer using BCG-tumor cell vaccines. *Prog Clin Biol Res.* 1989;310:51-65.
- [66] Jenkins S, Gritz L, Fedor CH, O'Neill EM, Panicali DL. Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus. *AIDS Res Hum Retroviruses.* 1991;7(12):991-8.
- [67] Marthas ML, Miller CJ, Sutjipto S, Higgins J, Torten J, Lohman BL, et al. Efficacy of live-attenuated and whole-inactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV. *J Med Primatol.* 1992;21(2-3):99-107.
- [68] Taylor J, Weinberg R, Tartaglia J, Richardson C, Alkhatib G, Briedis D, et al. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. *Virology.* 1992;187(1):321-8.
- [69] Arora DR, Gautam V, Arora B. HIV-1 therapeutic vaccine: A ray of hope. *Indian J Med Microbiol.* 2003;21(4):225-32.
- [70] Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. *Cell.* 2001;106(3):271-4.

- [71] Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. *Nat Med.* 2004;10(5):475-80.
- [72] Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. *Nat Med.* 1996;2(1):52-8.
- [73] Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. *J Clin Invest.* 2002;109(12):1519-26.
- [74] Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. *Cancer Res.* 2001;61(17):6451-8.
- [75] Bernhard H, Disis ML, Heimfeld S, Hand S, Gralow JR, Cheever MA. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. *Cancer Res.* 1995;55(5):1099-104.
- [76] Mackensen A, Herbst B, Chen JL, Kohler G, Noppen C, Herr W, et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. *Int J Cancer.* 2000;86(3):385-92.

- [77] Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, et al. Proliferating dendritic cell progenitors in human blood. *J Exp Med.* 1994;180(1):83-93.
- [78] Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. *J Exp Med.* 1994;179(4):1109-18.
- [79] Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. *J Clin Invest.* 2002;109(3):409-17.
- [80] Bozzacco L, Trumfheller C, Siegal FP, Mehandru S, Markowitz M, Carrington M, et al. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8<sup>+</sup> T cells in a spectrum of human MHC I haplotypes. *Proc Natl Acad Sci U S A.* 2007;104(4):1289-94.
- [81] Ratzinger G, Stoitzner P, Ebner S, Lutz MB, Layton GT, Rainer C, et al. Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin. *J Immunol.* 2002;168(9):4361-71.

- [82] Bousso P, Robey E. Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. *Nat Immunol.* 2003;4(6):579-85.
- [83] Garg S, Oran A, Wajchman J, Sasaki S, Maris CH, Kapp JA, et al. Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo. *Nat Immunol.* 2003;4(9):907-12.
- [84] Martín-Fontecha A, Sebastiani S, Hopken UE, Ugucioni M, Lipp M, Lanzavecchia A, et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. *J Exp Med.* 2003;198(4):615-21.
- [85] Miller MJ, Hejazi AS, Wei SH, Cahalan MD, Parker I. T cell repertoire scanning is promoted by dynamic dendritic cell behavior and random T cell motility in the lymph node. *Proc Natl Acad Sci U S A.* 2004;101(4):998-1003.
- [86] Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge TB, Paragnik L, et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. *Int J Cancer.* 2001;93(2):243-51.

- [87] Mullins DW, Sheasley SL, Ream RM, Bullock TN, Fu YX, Engelhard VH. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. *J Exp Med.* 2003;198(7):1023-34.
- [88] Maraskovsky E, Daro E, Roux E, Teepe M, Maliszewski CR, Hoek J, et al. In vivo generation of human dendritic cell subsets by Flt3 ligand. *Blood.* 2000;96(3):878-84.
- [89] Pulendran B, Banchereau J, Burkeholder S, Kraus E, Guinet E, Chalouni C, et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. *J Immunol.* 2000;165(1):566-72.
- [90] Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8<sup>+</sup> T cell tolerance. *J Exp Med.* 2002;196(12):1627-38.
- [91] Engering A, Geijtenbeek TB, van Kooyk Y. Immune escape through C-type lectins on dendritic cells. *Trends Immunol.* 2002;23(10):480-5.



- [92] Cerundolo V, Hermans IF, Salio M. Dendritic cells: a journey from laboratory to clinic. *Nat Immunol.* 2004;5(1):7-10.
- [93] Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. *J Exp Med.* 2002;195(10):1279-88.
- [94] Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. *Cancer Res.* 2001;61(23):8513-9.
- [95] Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. *Annu Rev Immunol.* 2000;18:767-811.
- [96] Mommaas AM, Mulder AA, Jordens R, Out C, Tan MC, Cresswell P, et al. Human epidermal Langerhans cells lack functional mannose receptors and a fully developed endosomal/lysosomal compartment for loading of HLA class II molecules. *Eur J Immunol.* 1999;29(2):571-80.

- [97] Mortarini R, Anichini A, Di Nicola M, Siena S, Bregni M, Belli F, et al. Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. *Cancer Res.* 1997;57(24):5534-41.
- [98] Mahnke K, Guo M, Lee S, Sepulveda H, Swain SL, Nussenzweig M, et al. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. *J Cell Biol.* 2000;151(3):673-84.
- [99] Kronin V, Wu L, Gong S, Nussenzweig MC, Shortman K. DEC-205 as a marker of dendritic cells with regulatory effects on CD8 T cell responses. *Int Immunol.* 2000;12(5):731-5.
- [100] Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. *Annu Rev Immunol.* 2002;20:621-67.
- [101] Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. *Nature.* 1998;392(6671):86-9.

- [102] Brigl M, Brenner MB. CD1: antigen presentation and T cell function. *Annu Rev Immunol.* 2004;22:817-90.
- [103] Goodman JW, Sercarz EE. The complexity of structures involved in T-cell activation. *Annu Rev Immunol.* 1983;1:465-98.
- [104] Banchereau J, Pulendran B, Steinman R, Palucka K. Will the making of plasmacytoid dendritic cells in vitro help unravel their mysteries? *J Exp Med.* 2000;192(12):F39-44.
- [105] Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R, et al. Reciprocal control of T helper cell and dendritic cell differentiation. *Science.* 1999;283(5405):1183-6.
- [106] Bell D, Young JW, Banchereau J. Dendritic cells. *Adv Immunol.* 1999;72:255-324.
- [107] Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. *Blood.* 1997;90(9):3245-87.
- [108] Inaba K, Witmer-Pack M, Inaba M, Hathcock KS, Sakuta H, Azuma M, et al. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. *J Exp Med.* 1994;180(5):1849-60.

- [109] Caux C, Vanbervliet B, Massacrier C, Azuma M, Okumura K, Lanier LL, et al. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. *J Exp Med*. 1994;180(5):1841-7.
- [110] Arriaga-Pizano L, Jimenez-Zamudio L, Vadillo-Ortega F, Martinez-Flores A, Herrerias-Canedo T, Hernandez-Guerrero C. The predominant Th1 cytokine profile in maternal plasma of preeclamptic women is not reflected in the choriondecidual and fetal compartments. *J Soc Gynecol Investig*. 2005;12(5):335-42.
- [111] Sommer F, Meixner M, Mannherz M, Ogilvie AL, Rollinghoff M, Lohoff M. Analysis of cytokine patterns produced by individual CD4+ lymph node cells during experimental murine leishmaniasis in resistant and susceptible mice. *Int Immunol*. 1998;10(12):1853-61.
- [112] Kawamura T, Gatanaga H, Borris DL, Connors M, Mitsuya H, Blauvelt A. Decreased stimulation of CD4+ T cell proliferation and IL-2 production by highly enriched populations of HIV-infected dendritic cells. *J Immunol*. 2003;170(8):4260-6.
- [113] Blauvelt A, Asada H, Saville MW, Klaus-Kovtun V, Altman DJ, Yarchoan R, et al. Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways. *J Clin Invest*. 1997;100(8):2043-53.

- [114] Blauvelt A, Clerici M, Lucey DR, Steinberg SM, Yarchoan R, Walker R, et al. Functional studies of epidermal Langerhans cells and blood monocytes in HIV-infected persons. *J Immunol.* 1995;154(7):3506-15.
- [115] Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. *Nature.* 1992;360(6401):258-61.
- [116] Freudenthal PS, Steinman RM. The distinct surface of human blood dendritic cells, as observed after an improved isolation method. *Proc Natl Acad Sci U S A.* 1990;87(19):7698-702.
- [117] Hart DN, McKenzie JL. Isolation and characterization of human tonsil dendritic cells. *J Exp Med.* 1988;168(1):157-70.
- [118] McIlroy D, Autran B, Cheynier R, Wain-Hobson S, Clauvel JP, Oksenhendler E, et al. Infection frequency of dendritic cells and CD4+ T lymphocytes in spleens of human immunodeficiency virus-positive patients. *J Virol.* 1995;69(8):4737-45.
- [119] Sotzik F, Rosenberg Y, Boyd AW, Honeyman M, Metcalf D, Scollay R, et al. Assessment of CD4 expression by early T precursor cells and by dendritic cells in the human thymus. *J Immunol.* 1994;152(7):3370-7.

- [120] Cameron P, Pope M, Granelli-Piperno A, Steinman RM. Dendritic cells and the replication of HIV-1. *J Leukoc Biol.* 1996;59(2):158-71.
- [121] Maher D, Wu X, Schacker T, Horbul J, Southern P. HIV binding, penetration, and primary infection in human cervicovaginal tissue. *Proc Natl Acad Sci U S A.* 2005;102(32):11504-9.
- [122] Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. *Nat Rev Microbiol.* 2003;1(1):25-34.
- [123] Groot F. Dendritic cell-mediated HIV-1 transmission [PhD thesis]: University of Amsterdam; 2006.
- [124] Pope M, Haase AT. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. *Nat Med.* 2003;9(7):847-52.
- [125] Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. *Annu Rev Immunol.* 2003;21:265-304.
- [126] Zhang Z, Schuler T, Zupancic M, Wietgreffe S, Staskus KA, Reimann KA, et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. *Science.* 1999;286(5443):1353-7.

- [127] Arrighi JF, Pion M, Garcia E, Escola JM, van Kooyk Y, Geijtenbeek TB, et al. DC-SIGN-mediated infectious synapse formation enhances X4 HIV-1 transmission from dendritic cells to T cells. *J Exp Med*. 2004;200(10):1279-88.
- [128] Frank I, Piatak M, Jr., Stoessel H, Romani N, Bonnyay D, Lifson JD, et al. Infectious and whole inactivated simian immunodeficiency viruses interact similarly with primate dendritic cells (DCs): differential intracellular fate of virions in mature and immature DCs. *J Virol*. 2002;76(6):2936-51.
- [129] Kwon DS, Gregorio G, Bitton N, Hendrickson WA, Littman DR. DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection. *Immunity*. 2002;16(1):135-44.
- [130] Lee B, Leslie G, Soilleux E, O'Doherty U, Baik S, Levroney E, et al. cis Expression of DC-SIGN allows for more efficient entry of human and simian immunodeficiency viruses via CD4 and a coreceptor. *J Virol*. 2001;75(24):12028-38.
- [131] Sanders RW, de Jong EC, Baldwin CE, Schuitemaker JH, Kapsenberg ML, Berkhout B. Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. *J Virol*. 2002;76(15):7812-21.

- [132] Trumfheller C, Park CG, Finke J, Steinman RM, Granelli-Piperno A. Cell type-dependent retention and transmission of HIV-1 by DC-SIGN. *Int Immunol.* 2003;15(2):289-98.
- [133] Turville S, Wilkinson J, Cameron P, Dable J, Cunningham AL. The role of dendritic cell C-type lectin receptors in HIV pathogenesis. *J Leukoc Biol.* 2003;74(5):710-8.
- [134] Turville SG, Santos JJ, Frank I, Cameron PU, Wilkinson J, Miranda-Saksena M, et al. Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. *Blood.* 2004;103(6):2170-9.
- [135] Fong L, Mengozzi M, Abbey NW, Herndier BG, Engleman EG. Productive infection of plasmacytoid dendritic cells with human immunodeficiency virus type 1 is triggered by CD40 ligation. *J Virol.* 2002;76(21):11033-41.
- [136] Lore K, Smed-Sorensen A, Vasudevan J, Mascola JR, Koup RA. Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells. *J Exp Med.* 2005;201(12):2023-33.
- [137] Muller-Trutwin M, Hosmalin A. Role for plasmacytoid dendritic cells in anti-HIV innate immunity. *Immunol Cell Biol.* 2005;83(5):578-83.



- [138] Patterson S, Rae A, Hockey N, Gilmour J, Gotch F. Plasmacytoid dendritic cells are highly susceptible to human immunodeficiency virus type 1 infection and release infectious virus. *J Virol.* 2001;75(14):6710-3.
- [139] Smed-Sorensen A, Lore K, Vasudevan J, Louder MK, Andersson J, Mascola JR, et al. Differential susceptibility to human immunodeficiency virus type 1 infection of myeloid and plasmacytoid dendritic cells. *J Virol.* 2005;79(14):8861-9.
- [140] Steinman RM. Some interfaces of dendritic cell biology. *Apmsis.* 2003;111(7-8):675-97.
- [141] Chougnet C, Gessani S. Role of gp120 in dendritic cell dysfunction in HIV infection. *J Leukoc Biol.* 2006;80(5):994-1000.
- [142] Barron MA, Blyveis N, Palmer BE, MaWhinney S, Wilson CC. Influence of plasma viremia on defects in number and immunophenotype of blood dendritic cell subsets in human immunodeficiency virus 1-infected individuals. *J Infect Dis.* 2003;187(1):26-37.
- [143] Grassi F, Hosmalin A, McIlroy D, Calvez V, Debre P, Autran B. Depletion in blood CD11c-positive dendritic cells from HIV-infected patients. *Aids.* 1999;13(7):759-66.

- [144] Chehimi J, Campbell DE, Azzoni L, Bacheller D, Pappasavvas E, Jerandi G, et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. *J Immunol.* 2002;168(9):4796-801.
- [145] Feldman S, Stein D, Amrute S, Denny T, Garcia Z, Kloser P, et al. Decreased interferon-alpha production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors. *Clin Immunol.* 2001;101(2):201-10.
- [146] Hsieh SM, Pan SC, Hung CC, Chen MY, Chang SC. Differential impact of late-stage HIV-1 infection on in vitro and in vivo maturation of myeloid dendritic cells. *J Acquir Immune Defic Syndr.* 2003;33(4):413-9.
- [147] Fantuzzi L, Purificato C, Donato K, Belardelli F, Gessani S. Human immunodeficiency virus type 1 gp120 induces abnormal maturation and functional alterations of dendritic cells: a novel mechanism for AIDS pathogenesis. *J Virol.* 2004;78(18):9763-72.
- [148] Wilflingseder D, Mullauer B, Schramek H, Banki Z, Pruenster M, Dierich MP, et al. HIV-1-induced migration of monocyte-derived dendritic cells is associated with differential activation of MAPK pathways. *J Immunol.* 2004;173(12):7497-505.


- [149] Fonteneau JF, Larsson M, Beignon AS, McKenna K, Dasilva I, Amara A, et al. Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. *J Virol.* 2004;78(10):5223-32.
- [150] Schmidt B, Ashlock BM, Foster H, Fujimura SH, Levy JA. HIV-infected cells are major inducers of plasmacytoid dendritic cell interferon production, maturation, and migration. *Virology.* 2005;343(2):256-66.
- [151] Yonezawa A, Morita R, Takaori-Kondo A, Kadowaki N, Kitawaki T, Hori T, et al. Natural alpha interferon-producing cells respond to human immunodeficiency virus type 1 with alpha interferon production and maturation into dendritic cells. *J Virol.* 2003;77(6):3777-84.
- [152] Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, Kavanagh DG, et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. *J Clin Invest.* 2005;115(11):3265-75.
- [153] Herbeuval JP, Hardy AW, Boasso A, Anderson SA, Dolan MJ, Dy M, et al. Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells. *Proc Natl Acad Sci U S A.* 2005;102(39):13974-9.

- [154] Del Corno M, Gauzzi MC, Penna G, Belardelli F, Adorini L, Gessani S. Human immunodeficiency virus type 1 gp120 and other activation stimuli are highly effective in triggering alpha interferon and CC chemokine production in circulating plasmacytoid but not myeloid dendritic cells. *J Virol.* 2005;79(19):12597-601.
- [155] Balabanian K, Harriague J, Decrion C, Lagane B, Shorte S, Baleux F, et al. CXCR4-tropic HIV-1 envelope glycoprotein functions as a viral chemokine in unstimulated primary CD4+ T lymphocytes. *J Immunol.* 2004;173(12):7150-60.
- [156] Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, et al. Cell migration: integrating signals from front to back. *Science.* 2003;302(5651):1704-9.
- [157] Weissman D, Rabin RL, Arthos J, Rubbert A, Dybul M, Swofford R, et al. Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. *Nature.* 1997;389(6654):981-5.
- [158] Wilson NS, El-Sukkari D, Belz GT, Smith CM, Steptoe RJ, Heath WR, et al. Most lymphoid organ dendritic cell types are phenotypically and functionally immature. *Blood.* 2003;102(6):2187-94.

- [159] Sanarico N, Ciaramella A, Sacchi A, Bernasconi D, Bossu P, Mariani F, et al. Human monocyte-derived dendritic cells differentiated in the presence of IL-2 produce proinflammatory cytokines and prime Th1 immune response. *J Leukoc Biol.* 2006;80(3):555-62.
- [160] Pitcher CJ, Quittner C, Peterson DM, Connors M, Koup RA, Maino VC, et al. HIV-1-specific CD4<sup>+</sup> T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. *Nat Med.* 1999;5(5):518-25.
- [161] Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, et al. Vigorous HIV-1-specific CD4<sup>+</sup> T cell responses associated with control of viremia. *Science.* 1997;278(5342):1447-50.
- [162] Younes SA, Yassine-Diab B, Dumont AR, Boulassel MR, Grossman Z, Routy JP, et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4<sup>+</sup> T cells endowed with proliferative capacity. *J Exp Med.* 2003;198(12):1909-22.
- [163] Malhotra U, Berrey MM, Huang Y, Markee J, Brown DJ, Ap S, et al. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. *J Infect Dis.* 2000;181(1):121-31.

- [164] Oxenius A, Price DA, Easterbrook PJ, O'Callaghan CA, Kelleher AD, Whelan JA, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8<sup>+</sup> and CD4<sup>+</sup> T lymphocytes. *Proc Natl Acad Sci U S A*. 2000;97(7):3382-7.
- [165] Gray CM, Lawrence J, Schapiro JM, Altman JD, Winters MA, Crompton M, et al. Frequency of class I HLA-restricted anti-HIV CD8<sup>+</sup> T cells in individuals receiving highly active antiretroviral therapy (HAART). *J Immunol*. 1999;162(3):1780-8.
- [166] Kalams SA, Goulder PJ, Shea AK, Jones NG, Trocha AK, Ogg GS, et al. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. *J Virol*. 1999;73(8):6721-8.
- [167] Knight SC, Stagg AJ. Antigen-presenting cell types. *Curr Opin Immunol*. 1993;5(3):374-82.
- [168] Girolomoni G, Ricciardi-Castagnoli P. Dendritic cells hold promise for immunotherapy. *Immunol Today*. 1997;18(3):102-4.
- [169] Cavanagh LL, Saal RJ, Grimmett KL, Thomas R. Proliferation in monocyte-derived dendritic cell cultures is caused by progenitor cells capable of myeloid differentiation. *Blood*. 1998;92(5):1598-607.

- [170] Tanaka H, Demeure CE, Rubio M, Delespesse G, Sarfati M. Human monocyte-derived dendritic cells induce naive T cell differentiation into T helper cell type 2 (Th2) or Th1/Th2 effectors. Role of stimulator/responder ratio. *J Exp Med.* 2000;192(3):405-12.



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่  
Copyright© by Chiang Mai University  
All rights reserved